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Introduction {#sec1}
============

Pericytes are a mural cell type defined by their "perivascular" association with endothelial cells (ECs) ([@bib3]). Found in microvessels throughout the body, pericytes play a vital role in the remodeling and stabilization of developing blood vessels during angiogenesis ([@bib23], [@bib30]). Pericytes are also an essential component of the blood-brain barrier (BBB), which is a selectively permeable collection of blood vessels that is also comprised primarily of ECs and astrocytes ([@bib15], [@bib27]). The BBB protects the CNS from circulating insults such as pathogens and immune cells, and mediates the transportation of substances into and out of the brain. A healthy BBB is comprised of ECs that form continuous tight junctions, imparting barrier properties to this structure. Pericytes wrap around the vasculature formed by ECs and secrete extracellular matrix proteins into the shared basement membrane, which provides structural stability to the BBB ([@bib2], [@bib5]). The abundance of pericytes in the BBB at a pericyte-to-endothelial ratio between 1:1 and 1:3, compared with peripheral blood vessels, underscores their importance in maintaining the health of the CNS. Indeed, pericyte dysfunction has been implicated in a number of neurodegenerative disorders including Alzheimer\'s disease (AD) ([@bib30]). Degeneration of pericytes has been observed in human postmortem tissue as well as mouse models of AD ([@bib8], [@bib19]). Specifically, loss of pericyte coverage and resulting BBB breakdown was observed in the cortex and hippocampus of AD mouse models ([@bib14], [@bib28]). Accumulation of perivascular beta-amyloid (Aβ), a hallmark of AD, has been shown to be toxic to pericytes ([@bib29]). In addition, the presence of *APOE4*, the single greatest genetic risk factor in late-onset AD, plays a role in pericyte degradation, accumulation of Aβ in the CNS, and breakdown of the BBB ([@bib8], [@bib25]).

Since their identification almost 150 years ago, pericytes have remained an elusive cell type to characterize due to their heterogeneous ontogeny. Quail-chick chimeras and lineage-tracing studies revealed a neural crest (NC) origin of pericytes destined for the forebrain, while mesoderm has been shown to give rise to pericytes of the brainstem, spinal cord, and mid-brain ([@bib6], [@bib10], [@bib18]). While many cell types can be identified by expression of unique surface molecules (also known as "markers"), pericytes share expression of multiple markers with other closely related mural cell types such as smooth muscle cells ([@bib15]). Despite this, a combination of PDGFRβ, CD13, CD146, and NG2 surface expression is commonly accepted to be suitable for distinguishing pericytes from other cell types ([@bib3]). Recently, markers to distinguish brain-resident pericytes from those of the periphery have been identified. These include *FOXF2*, *VTN*, and *FOXC1*, although none are entirely unique to pericytes ([@bib9], [@bib18], [@bib20]).

Pluripotent stem cells (PSCs) provide an alternative approach to both model and treat diseases. AD patient induced PSCs (iPSCs) allow the development of *in vitro* models of the BBB to improve our understanding of AD-mediated breakdown of the BBB. While protocols exist to generate the cell types of the BBB (ECs, astrocytes, and pericytes) from iPSC lines, a method to generate *brain-specific* pericytes from iPSCs does not currently exist ([@bib7], [@bib11], [@bib16]). To address this, we have developed two methods that rely on either mesoderm or NC induction to generate pericytes from iPSCs.

Results {#sec2}
=======

Differentiation of hPSCs into Mesoderm and NC {#sec2.1}
---------------------------------------------

We developed two differentiation protocols to generate mesoderm- and NC-derived pericytes from human PSCs (hPSCs) including human embryonic stem cells (hESCs; H9) or human iPSCs ([Figure 1](#fig1){ref-type="fig"}A). Our iPSC lines are derived from adult AD patients bearing *APOE4* ("AD6") or *APOE3* ("AD22") alleles and also healthy patients bearing the *APOE3* allele ("AD5"), collectively referred to as "AD" lines ([Table S1](#mmc1){ref-type="supplementary-material"}). To generate iPSC-derived pericytes, we first differentiated these lines into either mesoderm or NC ([Figure 1](#fig1){ref-type="fig"}A). hPSCs were grown in mesodermal induction medium (MIM) or a previously described NC induction medium containing the GSK3 inhibitor, CHIR 99021, to activate WNT signaling ([@bib12]) ([Figure 1](#fig1){ref-type="fig"}A). After 5 days in culture, MIM-treated hPSCs expressed the mesodermal marker KDR and mesodermal genes *MIXL1* and Brachyury (*TBXT*), but did not express NC marker HNK-1 or genes *PAX3*, *PAX7*, or *TFAP2A* ([Figures 1](#fig1){ref-type="fig"}B and 1D). While MIM-treated H9 cells expressed the NC marker CD271, this marker is also known to be expressed in mesoderm-derived mesenchymal progenitors and, alone, is not sufficient to identify NC populations ([Figure 1](#fig1){ref-type="fig"}B) ([@bib4], [@bib11]). Conversely, NC-derived cells expressed NC markers HNK-1 and CD271 with mild upregulation of KDR ([Figure 1](#fig1){ref-type="fig"}C). All NC-treated hPSC lines expressed NC genes *PAX3*, *PAX7*, and *TFAP2A*, and did not express mesodermal genes *MIXL1* and *TBXT* ([Figure 1](#fig1){ref-type="fig"}D). While NC-treated H9 hESCs only mildly upregulated *PAX7*, they expressed high levels of *PAX3* and *TFAP2A* ([Figure 1](#fig1){ref-type="fig"}D). These data indicate that mesoderm and NC cells can be generated using MIM and NC media, respectively.Figure 1Differentiation and Characterization of hPSCs into Mesoderm and NC-Derived Pericytes(A) Schematic diagram of mesoderm (MIM) and NC differentiation protocols. Five days following MIM and NC induction, cells were passaged and maintained in pericyte medium (PM) to produce mesoderm-derived pericytes (mPC) and neural crest-derived pericytes (ncPC).(B and C) Representative flow cytometry analyses for surface expression of mesodermal marker KDR, and NC markers HNK-1 and CD271 in hPSCs after 5 days in MIM (B) or NC media (C) compared with fluorescence minus one (FMO) control stain.(D) qRT-PCR analysis of mesodermal genes *TBXT* and *MIXL1* (left panel) and NC genes *PAX3*, *PAX7*, and *TFAP2A* expression (right panel) in hPSCs after 5 days in MIM (red) or NC media (blue). Gene expression was calculated relative to undifferentiated H9 hPSCs. Undifferentiated AD5 iPSCs showed similar expression as H9 hPSCs (data not shown).Mean ± SD was calculated from triplicate reactions of three to six biological replicates. Statistical significance in was determined using the Student\'s unpaired t test (^∗∗^p \< 0.05, ^∗∗∗^p \< 0.01, ^∗∗∗∗^p \< 0.001).

Pericyte Induction of hPSC-Derived Mesoderm and NC Cells {#sec2.2}
--------------------------------------------------------

Following mesoderm and NC induction, cells were passaged and maintained in pericyte medium, which is a proprietary medium that supports pericyte growth, to initiate pericyte differentiation. After 5 days in pericyte medium, mesoderm-derived pericytes (mPCs) and NC-derived PCs (ncPCs) exhibited high expression of pericyte cell-surface markers PDGFRβ, NG2, CD13, and CD146 at levels comparable with primary human brain vascular pericytes (HBVPs) ([Figure 2](#fig2){ref-type="fig"}A). All three pericyte populations were negative for expression of the hemato-endothelial marker CD34 ([Figure 2](#fig2){ref-type="fig"}A), and expressed only low levels of the smooth muscle marker, α-smooth muscle actin ([Figure S1](#mmc1){ref-type="supplementary-material"}A), further confirming the pericyte-like identity of the iPSC-PCs. Both mPCs and ncPCs maintained consistent growth rates ([Figure S1](#mmc1){ref-type="supplementary-material"}B) and stable expression of pericyte markers throughout early to late passages ([Figures S1](#mmc1){ref-type="supplementary-material"}C and S1D).Figure 2Gene Expression Analysis of Pericyte Genes in ncPCs and mPCs(A) Representative flow cytometry analysis of pericyte (PDGFRβ, NG2, CD13, and CD146) and hemato-endothelial (CD34) markers in human brain vascular pericytes (HBVPs) (green, top row), mPC (red, middle row), and ncPC (blue, bottom row). The percentage of differentiated cells positive for each marker is shown for the stained cell (colored histograms) compared with the FMO controls (gray histograms). mPCs and ncPCs shown were derived from AD5 iPSCs and are representative of all hPSC lines.(B) qRT-PCR of pericyte genes *PDGFRB*, *ANGPT1*, *VTN*, *FOXC1*, and *FOXF2* in undifferentiated hPSCs (white), HBVPs (green), mPCs (red), and ncPCs (blue). Gene expression was normalized to *RPLP0* and calculated relative to HBVPs. Mean ± SD was calculated from triplicate reactions of three to six biological replicates.(C) Western blot of FOXF2 (top row) and VTN (middle row) protein in undifferentiated iPSCs, HBVPs, mPCs, and ncPCs. GAPDH protein (bottom row) was used as a loading control.See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

To determine the brain specificity of mPCs and ncPCs, we examined the expression of three recently identified brain pericyte genes: vitronectin (*VTN*), and forkhead transcription factors *FOXF2* and *FOXC1*. Pericytes secrete VTN, which upregulates vascular endothelial growth factor A signaling in ECs, and both *FOXC1* and *FOXF2* are required for proper brain pericyte differentiation and angiogenesis during embryonic development ([@bib18], [@bib20], [@bib24]). qRT-PCR analysis of these candidate brain-specific pericyte genes revealed that all three pericyte populations expressed *VTN* and *FOXC1*, although only ncPCs weakly expressed *FOXF2* ([Figure 2](#fig2){ref-type="fig"}B). By western blot, VTN and FOXF2 protein were both expressed across all mPC and ncPC lines ([Figure 2](#fig2){ref-type="fig"}C). Together this indicates that cells bearing expression of pericyte and *brain-specific* pericyte genes can be generated from iPSCs through both mesodermal and NC routes.

Functional Validation of Pericyte Interaction with ECs {#sec2.3}
------------------------------------------------------

During embryonic development, brain ECs recruit pericytes to the developing BBB, resulting in their tight association which drives maturation of the developing vessel ([@bib15]). Thus, a key functional property of pericytes is their ability to physically associate with ECs to support formation of lumenized vascular structures ([@bib24]). To test this capability in hPSC-derived PCs, we cultured HBVPs, ncPCs, or mPCs in a semi-solid fibrin gel matrix in a 3D culturing system with human endothelial colony-forming cell-ECs (ECFC-ECs) ([Figure 3](#fig3){ref-type="fig"}A). ECFC-ECs were chosen as the source of ECs because these cells are plastic and robust in adapting to a tissue-specific EC phenotype in the proper native environment ([@bib21], [@bib26]). ECFC-ECs cultured alone were unable to form extensive, lumenized vascular structures. However, when co-cultured with HBVPs, mPCs, or ncPCs, ECs formed elongated tube-like structures in close association with the PCs ([Figure 3](#fig3){ref-type="fig"}A). Quantification of EC tube length confirmed observations that mPCs and ncPCs contribute to vasculogenic tube assembly over ECFC-ECs alone ([Figure 3](#fig3){ref-type="fig"}B). These data demonstrate that both mesoderm- and NC-derived PCs support vessel growth and maturation.Figure 3iPSC-Derived Pericytes Promote EC Function(A) ECFCs (EC, red) and pericytes (PC, green) co-cultured in 3D tube formation assay. ECFCs were cultured alone or co-cultured with HBVPs, mPCs, and ncPCs and imaged after 1 day (top row) or 4 days (bottom row) in culture. Scale bars, 100 μm.(B) Percent (%) relative tube length of ECs cultured alone (gray) or with HBVPs (green), mPCs (red), or ncPCs (blue) was calculated relative to the tube length at day 1 of ECs cultured alone. Mean ± SD was calculated from three to five biological replicates. mPCs and ncPCs were derived from AD5 iPSCs and are representative of all hPSC-PCs.(C) Representative flow cytometry analysis of endothelial markers CD144 and GLUT1 in iPSC-derived brain microvessel endothelial cells (BMECs).(D) Schematic diagram of transwell system used to co-culture BMECs with pericytes to determine transendothelial electrical resistance (TEER).(E) Representative TEER values of BMECs that were cultured alone (gray) or with HBVPs (green), mPC (red, left graph), or ncPCs (blue, right graph). Mean ± SD was calculated from triplicate transwell reactions. mPCs and ncPCs were derived from AD5 iPSCs.(F) Quantification of peak TEER values at 48 h post co-culture of BMEC monocultures compared with co-culture with pericyte lines derived from multiple iPSC lines (H9, AD5, and AD22) and averaged across multiple experiments.Mean ± SD was calculated from three to six biological replicates in triplicate transwell reactions. Statistical significance in (B) and (F) was determined using the Student\'s unpaired t test (^∗∗^p \< 0.05, ^∗∗∗^p \< 0.01, ^∗∗∗∗^p \< 0.001). See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

Effects of Pericytes on Barrier Properties of ECs {#sec2.4}
-------------------------------------------------

Electrical resistance across an endothelial layer is a crucial physiological property that can be used to examine the strength of various barrier systems ([@bib22]). Specifically, the blood-brain barrier exhibits elevated transendothelial electrical resistance (TEER) values due to the tight junctions that form between ECs in the BBB. Multiple groups have shown that TEER values are significantly elevated in brain ECs cultured with HBVPs, suggesting that pericytes are essential to the integrity of an *in vitro* BBB system ([@bib13]). To test whether ncPCs and mPCs improve TEER values in a brain vascular context, brain microvessel endothelial cells (BMECs) were differentiated from AD5 iPSCs according to a previously described protocol ([@bib13]). We focused on the healthy patient AD5 iPSC line to have a consistent and healthy source of BMECs across all PC lines. AD5 BMECs, which express endothelial markers CD144 and GLUT1 ([Figure 3](#fig3){ref-type="fig"}C), were then monocultured or co-cultured with mPCs, ncPCs, or HBVPs in a transwell system and TEER was measured over the course of several days ([Figure 3](#fig3){ref-type="fig"}D). All PC lines appeared healthy and morphologically normal during the co-culture in EC medium (EGM2, data not shown). BMECs cultured alone displayed lower TEER values and, therefore, weaker barrier properties compared with BMECs co-cultured with mPCs or ncPCs ([Figure 3](#fig3){ref-type="fig"}E). Peak TEER values were observed 2 days following initiation of co-culture ([Figure 3](#fig3){ref-type="fig"}F). These observations were consistent across BMECs derived from different hPSC lines including AD22 iPSCs and H9 hESCs ([Figure S2](#mmc1){ref-type="supplementary-material"}). While BMEC quality, as measured by BMEC-only TEER values, varied across different experiments, the trends remained the same; maximal TEER is achieved when co-cultured with pericytes. Furthermore, maximal BMEC TEER was observed at day 2 of co-culture with pericytes, which supports the findings of previous studies ([@bib1], [@bib13]).

Effect of WNT Inhibition on NC-Derived Pericytes {#sec2.5}
------------------------------------------------

Our results suggest that brain pericytes can be generated through two distinct pathways. To further investigate the differences in these two routes, we focused on WNT signaling, which is required for NC induction but not mesoderm. Given the important role of WNTs in both NC induction, brain-specification of ECs, and BBB development, we reasoned that inhibition of WNT signaling would also have an impact on NC-derived pericyte induction. The WNT inhibitor DKK1 was added during mesoderm ([Figure S3](#mmc1){ref-type="supplementary-material"}) and NC induction of hPSCs ([Figure 4](#fig4){ref-type="fig"}). We found that while WNT inhibition had no effect on mesoderm induction ([Figure S2](#mmc1){ref-type="supplementary-material"}B), expression of *PAX7* appeared dramatically reduced in NC differentiation when WNT was inhibited ([Figure 4](#fig4){ref-type="fig"}B). However, after 5 days in pericyte medium, pericyte-like cells with expression of the pericyte markers PDGFRβ and CD146 were observed regardless of whether WNT was inhibited (DKK1) or activated (CHIR) during NC induction, although other pericyte markers CD13 and NG2 were downregulated after WNT inhibition ([Figure 4](#fig4){ref-type="fig"}C). DKK1-treated cells also appeared to exhibit lower expression of the brain-specific pericyte genes *VTN* and *FOXF2*, but higher expression of *FOXC1* compared with CHIR-treated cells ([Figure 4](#fig4){ref-type="fig"}D). This suggests that WNT signaling is not necessary for pericyte specification, although WNT signaling appears to play a role in completing pericyte development through the NC pathway.Figure 4Effect of WNT Inhibition on NC-Derived Pericyte Induction(A) Schematic diagram of NC differentiation protocol supplemented with the WNT activator CHIR99021 (top row) or with the WNT inhibitor DKK1 (bottom row) for 5 days, then passaged and maintained in pericyte medium (PM).(B) qRT-PCR analysis of NC gene *PAX7* expression in undifferentiated hPSCs (gray) or hPSCs after 5 days in NC supplemented with CHIR99021 or DKK1. Mean ± SD was calculated from triplicate reactions of two biological replicates.(C) Representative flow cytometry analysis of pericyte marker expression in pericytes derived from NC supplemented with CHIR99021 (blue) or DKK1 (orange) after passage into PM for 3--7 days. The FMO control (gray histogram) was used to define the gate (dashed line) used to calculate the percentage of cells positive for each marker, which is shown.(D) qRT-PCR of pericyte genes *VTN*, *FOXC1*, and *FOXF2* in cells derived from NC supplemented with CHIR99021 (blue) or DKK1 (orange) after passage into PM. Gene expression was normalized to *RPLP0* and calculated relative to undifferentiated hPSCs (gray). Mean ± SD was calculated from triplicate reactions of two biological replicates.See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

Discussion {#sec3}
==========

In this study, we developed two methods to generate brain pericyte-like cells from hPSCs through mesodermal (mPC) or neural crest (ncPC) routes. While both mPCs and ncPCs exhibited similar pericyte gene expression and functional properties, subtle differences between them were observed. Both populations displayed robust marker expression of PDGFRβ, NG2, CD13, and CD146, but *FOXF2* gene expression was higher in ncPCs. During development, *FOXF2* is expressed in the NC, which might explain its higher expression in ncPCs as opposed to mPCs ([@bib17]). We find that, while mPCs and ncPCs display slight differences in the expression of certain genes, they are functionally similar. Surprisingly, despite the requirement for WNT signaling in NC induction, pericytes could still be generated via this route when WNT was inhibited. This raised the possibility that the ncPCs may derive from a rare population during NC differentiation that is independent of WNT. We hypothesized this might be mesoderm, but there was no *TBXT* expression in DKK1-treated NC cells (data not shown). Future RNA sequencing studies are necessary to determine precisely how similar these two PC cell types are.

In summary, our study shows that human pericyte-like cells can be generated from hESCs and iPSCs using two distinct protocols. Both mesoderm and NC induction routes are easy to perform, use fully defined serum-free components, and produce pericytes with consistent marker expression and functional properties through multiple passages and freeze-thaw cycles. Both PC types are easy to transfect, and can be sorted by fluorescence-activated cell sorting (FACS) if necessary. We have multiple, independently generated mPC and ncPC lines from a variety of healthy and AD patient iPSC lines representing *APOE3/3* and *APOE4/4* genotypes ([Table S1](#mmc1){ref-type="supplementary-material"}). These pericyte-like cells can be used as a tool to investigate the role of pericytes in healthy and diseased BBB contexts. Future studies will compare the impact of *APOE* polymorphism on BBB function, which could identify new therapeutic targets to restore BBB function and mitigate AD pathology.

Experimental Procedures {#sec4}
=======================

PSC Culture {#sec4.1}
-----------

hPSC lines were cultured in TeSR-E8 medium (STEMCELL Technologies) on Matrigel-coated plates (Corning). Human iPSC lines were provided by the University of California Irvine Alzheimer\'s Disease Research Center (UCI-ADRC). All procedures using pluripotent stem cell lines were approved by UCI\'s human stem cell research oversight committee. See [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"} for more details.

Primary Cell Culture {#sec4.2}
--------------------

Primary HBVPs (ScienCell) were grown in pericyte medium (1201, ScienCell) according to the manufacturer\'s instructions. ECFC-ECs were a gift from Dr. Christopher Hughes\' laboratory, and are cultured in EGM-2 medium (Lonza). See [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"} for more details.

Differentiation of hPSCs into Mesoderm and NC-Derived Pericyte-like Cells {#sec4.3}
-------------------------------------------------------------------------

hPSCs were passaged as single cells onto Matrigel-coated plates in either MIM (STEMCELL Technologies) or a previously described NC induction medium ([@bib12]) for 5 days to initiate mesoderm and NC, respectively. Resulting cells were passaged into pericyte medium (1201, ScienCell) for pericyte specification. See [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"} for more details.

Differentiation of hPSCs into BMECs {#sec4.4}
-----------------------------------

BMEC differentiation was performed according to a previously established protocol ([@bib13]). See [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"} for more details.

3D Tube Formation Assay {#sec4.5}
-----------------------

ECFC-ECs were combined with or without HBVPs, mPCs, or ncPCs in a semi-solid fibrin matrix at a cell ratio of 50:1. Cells were imaged everyday using an Olympus FV3000 Laser-Scanning Confocal and tube length was quantified using Angiotool software. See [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"} for more details.

Transwell TEER Assay {#sec4.6}
--------------------

iPSC-derived BMECs were seeded onto transwell filters (Corning) that were placed into 12-well plates containing HBVPs, ncPCs, or mPCs. TEER measurements were made every 24 h. See [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"} for more details.
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